Ferring Pharmaceuticals awarded for their no-needle HGH
Buy GenF20 HGH, Buy hgh, Guide, HGH products, HGH: Human Growth Hormone, HgH, Hgh Effects, News, Review, Tips
The 2008 Frost & Sullivan European Human Growth Hormone Competitive Strategy Leadership Award has been presented to Ferring Pharmaceuticals which is headquartered in Switzerland and identifies, develops and markets innovative products in the areas of endocrinology, gastroenterology, urology, infertility and obstetrics. The award is in recognition of Ferring’s initiatives in providing ZOMAJET 2 VISION and ZOMAJET VISION X, innovative no-needle delivery systems for its human growth hormone, ZOMACTON.
These novel, no-needle delivery systems will definitely help Ferring to not only sustain its market share in the European growth hormones market, but also to expand its presence in the HGH market worldwide.
“Drug delivery systems provide strategic differentiation to successfully increase sales for companies established in the HGH market,” said Frost & Sullivan Research Analyst Prabakar Sampath adding, “Through its innovation in no-needle devices, and clinical evidence showing the high level of childrens’ preference for no-needle HGH administration, Ferring has shown leadership in meeting the needs of the paediatric population in this therapy area.”
The majority of end users of HGH are children under the age of fifteen most of whom stop using HGH due to the inconvenience caused by the traditional HGH injections. This poor compliance is attributed to ‘needle-phobia’ and pain caused while administering injections.
Popularity: 1% [?]
 |
   |
These novel, no-needle delivery systems will definitely help Ferring to not only sustain its market share in the European growth hormones market, but also to expand its presence in the HGH market worldwide.